FDA panel endorses Allos' lymphoma drug Folotyn

09/3/2009 | Reuters

An FDA panel voted 10-4 to recommend the approval of Folotyn, Allos Therapeutics' candidate for peripheral T-cell lymphoma. The experts concluded that although the rate of patient response was not impressive overall, clinical results were strong enough to demonstrate Folotyn's benefit to certain PTCL patients who failed to respond to other therapies.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care